Walleye Capital LLC Takes Position in OptimizeRx Co. (NASDAQ:OPRX)

Walleye Capital LLC acquired a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 138,575 shares of the company's stock, valued at approximately $673,000. Walleye Capital LLC owned 0.75% of OptimizeRx at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in shares of OptimizeRx in the 4th quarter valued at about $25,000. SG Americas Securities LLC purchased a new stake in OptimizeRx in the fourth quarter valued at approximately $51,000. Wells Fargo & Company MN lifted its position in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares during the last quarter. Barclays PLC lifted its position in OptimizeRx by 13.5% during the fourth quarter. Barclays PLC now owns 30,574 shares of the company's stock valued at $148,000 after purchasing an additional 3,640 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in OptimizeRx in the 4th quarter worth approximately $178,000. Hedge funds and other institutional investors own 76.47% of the company's stock.

Insider Buying and Selling at OptimizeRx

In other news, Director James Paul Lang bought 321,408 shares of the company's stock in a transaction dated Friday, March 14th. The stock was bought at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. This trade represents a 472.35 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Lake Street Capital reaffirmed a "buy" rating and set a $11.00 price objective on shares of OptimizeRx in a report on Tuesday, December 24th. B. Riley upgraded OptimizeRx to a "strong-buy" rating in a report on Wednesday, March 12th. JMP Securities restated a "market outperform" rating and issued a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $9.06.

OptimizeRx Stock Performance

NASDAQ:OPRX opened at $8.20 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx Co. has a fifty-two week low of $3.78 and a fifty-two week high of $14.13. The firm has a market cap of $151.62 million, a PE ratio of -6.17 and a beta of 1.18. The business has a 50 day moving average price of $7.23 and a 200-day moving average price of $6.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.